title: Tomographic ventilation/perfusion lung scintigraphy in the monitoring of the effect of treatment in pulmonary embolism: serial follow-up over a 6-month period.
abstract: BACKGROUND
  Pulmonary embolism (PE) is a severe condition with nonspecific symptoms. Diagnosis relies on medical imaging but follow-up is currently based on clinical symptoms and general risk factors. The duration of anticoagulant treatment after an acute episode of PE is still subject to debate and the best method of identifying the risk of recurrence in individual patients is undefined. Tomographic lung scintigraphy [ventilation/perfusion single photon emission computed tomography (V/P SPECT)] has improved the diagnostic accuracy with regard to PE but has not been evaluated for PE follow-up.
  
  
  OBJECTIVE
  The aim of this prospective study was to quantitatively follow the natural history of treated PE using V/P SPECT, which could prove helpful in defining an anticoagulant treatment regime for individual patients.
  
  
  METHODS
  Of 83 consecutive patients with clinically suspected PE examined with V/P SPECT, 23 patients with confirmed PE were followed by serial V/P SPECT examinations over a 6-month period. All patients were also followed clinically.
  
  
  RESULTS
  The mean relative decrease in PE extent compared with the time of diagnosis was 54±26% at 2 weeks, 79±30% at 3 months, and 82±30% at 6 months. Significant resolution of mismatched perfusion defects occurred between V/P SPECT controls within the first 3 months of anticoagulation (P<0.001) but not thereafter. V/P SPECT identified four patients with chronic PE, even though all patients were free from symptoms at 3-month follow-up.
  
  
  CONCLUSIONS
  Follow-up of PE with V/P SPECT is feasible to evaluate treatment effectiveness in individual patients and to identify patients that develop chronic PE. This study also confirms that resolution of perfusion defects after PE occurs within the first 3 months of treatment. It is therefore recommended that V/P SPECT follow-up should be considered at 3 months after diagnosis.
authors.affiliation: Clinic for Nuclear Medicine, Clinical Center, University Hospital of Sarajevo, Sarajevo, Bosnia.
authors.forename: Amela
authors.initials: A
authors.lastname: Begic
authors.forename: Jonas
authors.initials: J
authors.lastname: Jögi
authors.forename: Amra
authors.initials: A
authors.lastname: Hadziredzepovic
authors.forename: Elma
authors.initials: E
authors.lastname: Kucukalic-Selimović
authors.forename: Sadzida
authors.initials: S
authors.lastname: Begovic-Hadzimuratovic
authors.forename: Marika
authors.initials: M
authors.lastname: Bajc
mesh_terms: D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007753:Laboratories; D008168:Lung / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000503:physiopathology; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome; D014692:Ventilation-Perfusion Ratio / Q000187:drug effects*
chemical_list: D000925:Anticoagulants